Perspectives Stories and opinions behind our scientific excellence
-
Let’s Get Real About Skin Cancer
Andre Spring
Let’s Get Real About Skin Cancer
-
Applying Emerging AI and
Machine Learning Tools to Find
Equitable Solutions
to Scientific DiscoveryJeffrey Reid
Read about Applying Emerging AI and Machine Learning Tools to Find Equitable Solutions to Scientific Discovery
-
A Compliance Program with Science and Patients at the Core
Melissa Lozner
Read about Regeneron Compliance Program
-
HITTING THE “ON SWITCH” IN
HEARING LOSSMeghan Drummond, PhD
Vassili Valayannopoulos, MD, PhD, MBA
Vassili Valayannopoulos and Meghan (Meg) Drummond talk about Regeneron’s auditory program and the development of a targeted gene therapy platform to treat disorders like congenital hearing loss.
-
Innovating for Good
Linnea Texin
Read about Innovating for Good
-
The RGC Effect: A Decade in the Making
Aris Baras, MD
Read about the RGC Effect
-
Striving to Make a Big Impact in Cancer Care
Israel Lowy, M.D., Ph.D.
How we are leading a charge to close the care gap in cancer treatment on World Cancer Day and everyday
-
Advancing African Ancestry Representation in Genomic Research and STEM Education
Lyndon Mitnaul, PhD
Driven to make a difference through the Together for CHANGE Initiative
-
Prioritizing Eye Health With the Gr8 Eye Movement
Kevin Clark
Driving awareness for serious retinal diseases among impacted groups with a patient-focused disease awareness campaign.
-
Biomarkers Go Digital
Bari Kowal
Biomarkers Go Digital
-
Changing the Paradigm in COPD: Rethinking the Science & Removing Barriers
Bola Akinlade, MD, MBA, FACP
Changing the Paradigm in COPD: Rethinking the Science & Removing Barriers
-
An Unequivocal Victory for Innovation
Len Schleifer, MD, PhD, President and Chief Executive Officer
A recent Supreme Court decision helps patients by protecting the scientific innovation emerging from America’s thriving biopharma community
-
Responsible Innovation: Taking a Holistic Approach to Our Mission to Improve Lives
Linnea Texin
Unlocking the power of our business to “Do Well by Doing Good”
-
Our Impact on Diseases of the Retina: Always Striving for Innovation
Kimberly Reed
Our Impact on Diseases of the Retina: Always Striving for Innovation
-
More Genomics, Less Fear
Adolfo Ferrando, MD, PhD
The genome is the how and why that define us
-
Going “all in” with liver disease genetics
Luca A. Lotta, MD, PhD
The "Team Science" approach leading to the discovery of CIDEB mutations that protect from liver disease
-
Defining Internship Experiences
Regina Thomas
Nurturing the Next Generation of Scientific Innovators
-
Using data for good
Potoula Stavropoulos
Transformative impact through skills-based volunteering
-
It Takes a Village
Viktoria (Vika) Gusarova
Sergio Fazio
Regeneron scientists discuss efforts that paved the way for a treatment for an ultra-rare, inherited disease of high cholesterol
-
Striving for Impact through Responsibility
Christina Chan
Regeneron is committed to achieving our Global Responsibility Goals by 2025. Read the steps we're taking in the 2021 Responsibility Report.
-
Paving the Way for a Better Workplace, Better Science, and a Better World
Smita Pillai
Regeneron’s first Chief Diversity, Equity & Inclusion (DEI) Officer, Smita Pillai, explains how leadership through action is ensuring our presence in biotech is mindful, equitable and intersectional.
-
Helping the several million immunocompromised Americans who are still “Prisoners of the Pandemic”
George D. Yancopoulos, MD, PhD
Regeneron has received numerous queries about making our REGEN-COV® (casirivimab and imdevimab) antibody cocktail available to protect immunocompromised individuals who do not respond to COVID19 vaccines. This blog reflects our thinking and the current scientific evidence related to this question.
-
Staying Safe through Science
Elizabeth Green
Learn about Regeneron's Environment Health & Safety (EH&S) team and how it navigates a constantly changing business environment.
-
A New Breakthrough in the Search for Protective Genetics – and the Medicines that Mimic Them
Aris Baras, MD
Learn more about protective genetic variants and the Regeneron Genetics Center's discovery of the GPR75 protective gene associated with reduced body weight and obesity risk.
-
Data Privacy is in our DNA
Ericka Watson
Learn more about the importance of data privacy and how Regeneron works to safeguard personal data, including genetic data. See our Data Privacy Philosophy for more information.
-
Two targets may be better than one
Israel Lowy, MD, PhD
Andres Sirulnik, MD, PhD
Regeneron leaders Andres Sirulnik and Israel Lowy discuss why they believe bispecific antibodies may be the next class of medicines to revolutionize cancer treatment.
-
Chatting with Young Scientists
Erin Oswald
Regeneron is committed to fostering the next generation of scientific innovators who can solve society's greatest challenges. Hear from our own research scientist as she discusses career paths in science with two winners of the 2020 Regeneron Science Talent Search.
-
The Regeneron Journey: 2020 Edition
Len Schleifer, MD, PhD
Following an Emergency Use Authorization for casirivimab and imdevimab, Len Schleifer, MD, PhD, Founder and CEO, reflects on what the Regeneron team has accomplished so far in 2020.
-
Advancing our commitment to diversity, equity & inclusion
Maya Bermingham
Find out how Regeneron is fostering diversity, equity and inclusion in the workplace and communities to extend our mission to improve lives.
-
Raising The Bar For Corporate Responsibility In The Biotech Industry
Hala Mirza
Introducing Regeneron's new global corporate responsibility goals. The 12 goals span three key areas and set us up for ESG success.
-
Working Together To Provide Covid-19 Testing Components
Dan Van Plew
The Regeneron IOPS team donated time and supplies to create a critical component for 500K COVID-19 testing kits, which were used this spring to fight the pandemic in New York State.
-
A Million Is Just The Beginning
John Overton, PhD
The Regeneron Genetics Center® (RGC™) just celebrated sequencing its one millionith exome. Learn how we got here and what we're aiming for next.
-
Pioneers In Antibody Medicine
Drew Murphy, PhD
Antibodies have been at the heart of our research efforts for nearly thirty years, and some might say they are finally stepping into the limelight. See how antibodies are used as new and established medicines, including for infectious diseases.
-
Tapping Preclinical Understanding For Smarter Trials
Dimitris Skokos, PhD
Elizabeth Miller
The story behind Regeneron’s first costimulatory bispecific clinical trial
-
Nurturing The Spark & Celebrating Stars
Hala Mirza
Our long-term commitment to fostering the next generation of scientists.
-
Addressing Painful Memories From Within
Susan Croll, PhD
Understanding the biological challenges to treating pain
-
Seeing A New Way For Diabetic Retinopathy
Alyson Berliner, MD, PhD
Robert Vitti, MD
Regeneron scientists discuss their motivations for studying diabetic retinopathy, as they work to establish new treatment approaches but also shift mindset around the disease.
-
Listening & Learning From The Rare Disease Community
Amanda Seeff-Charny
Speaking with people who are actually living with rare diseases is critical to help bring meaningful change, especially when there are few or no treatment options. Learn how patients strengthen our science and potential impact.
-
Jumping Across The Pond With Success
Niall O’Leary
Niall O'Leary, VP Site Head of Industrial Operations and Product Supply in Ireland, shares his story of making an American company 'work' in Ireland by embodying shared values.
-
Making Innovation Matter For Patients
David Weinreich, MD
David Weinreich, Head of Global Clinical Development, discusses the value of thoughtful innovation in biotech and how Regeneron works to put patients first.
-
You Could Call Us Corporate Responsibility Trendsetters
Hala Mirza
Hala Mirza, SVP of Corporate Communications and Citizenship, discusses the 'trendiness' of corporate responsibility and explains Regeneron's own responsibility strategy.
-
The Heroes And Problem Solvers Of Tomorrow
George Yancopoulos, MD, PhD
Learn about the Regeneron Science Talent Search and the diverse group of 40 finalists who will present their STEM-focused research to industry leaders, members of Congress and the National Geographic Society.
-
Stacking The Deck For Genetic Discovery
Alan Shuldiner, MD
Genetic 'founder populations' such as the Amish community help scientists accelerate their research, often enabling discoveries that can help improve health in these very same populations.
-
Looking Forward With Hope
George Yancopoulos, MD, PhD
How does society overcome the challenges of disease, food insecurity and climate change? We think one way is through support of the Regeneron Science Talent Search, where passionate, skilled young people bring fresh perspectives to significant global problems.
-
The Real Healthcare Problem Is Bigger Than You Think
George Yancopoulos, MD, PhD
Len Schleifer, MD, PhD
The current view of the biopharma industry tends to focus on short-term issues. But, we fear there are even more important longer-term threats to human health at stake and encourage people to understand why investment in innovation is more important than ever.
-
Making A Drug You Hope No One Will Ever Need
Neil Stahl, PhD
Twenty-five years of discovery and development of medicines at Regeneron have helped millions of people. Leveraging the power of collaboration, we are now working on a medicine to treat Ebola. This is the story of REGN-EB3; a drug we hope no one will ever need.
-
When The Student Is A Computer: Teaching Machines To Do New Tricks
Jeffrey Reid, PhD
Want a revolution in genomics? Pair lightning-fast, computational pattern recognition with an unprecedented amount of health data. The RGC® is leveraging the power of artificial intelligence and machine learning to do just that.
No results found. Please adjust your filter selection and try again.